Search results
Results from the WOW.Com Content Network
The company's stock was trading slightly up on the news early Monday before falling after market open. Moderna is up almost 20% in the last month after the company received approval from the FDA ...
The approval was updated in September 2021, to include people aged twelve and older. [14] The Moderna Spikevax COVID-19 vaccine was authorized in Canada in September 2021, for people aged 12 and older. [22] [4] [182] The Moderna Spikevax COVID-19 vaccine was authorized in the US in January 2022, for people aged 18 and older. [1] [38] [41]
Moderna is also expecting to get approval to expand the label to high-risk people under the age of 60. It sees the expansion of the product to younger adults as having a $10 billion total ...
Moderna held its annual R&D day this week. Moderna's (NASDAQ: MRNA) struggles may last a little longer than expected. The biotech company had seen both sales and its stock price plummet as demand ...
Yahoo Finance’s Brian Sozzi and Alexis Christoforous break down the market action for Moderna, after the company announced it received FDA clearance for its coronavirus vaccine for phase 2 trial.
In March 2020, the Food and Drug Administration approved clinical trials for the Moderna COVID‑19 vaccine candidate, and in December, the vaccine, mRNA-1273, was issued an emergency use authorization in the United States. [35] [36] In 2022, it gained FDA approval both for the monovalent vaccine, Spikevax, and a bivalent booster. [37]
Thursday, the FDA granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron ...
The FDA authorizes the first bivalent COVID-19 booster for ages 5-11. ... CDC approves Pfizer, Moderna's COVID-19 boosters for ages 5 and up. Anjalee Khemlani. October 12, 2022 at 10:24 AM.